Galmed Pharmaceuticals Ltd. (GLMD) Stock
GLMD Key Statistics
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.
CEO: Allen Baharaff. Company website
GLMD — Frequently Asked Questions
What is the GLMD stock price today?
Galmed Pharmaceuticals Ltd. (GLMD) trades at $0.49, down 4.23% on the day, as of Sep 20, 2026 14:58 UTC.
What is Galmed Pharmaceuticals Ltd.'s market cap?
Galmed Pharmaceuticals Ltd. has a market capitalisation of $2.69M, calculated from the live GLMD share price and shares outstanding.
What is the P/E ratio of GLMD?
GLMD has no meaningful price-to-earnings ratio: Galmed Pharmaceuticals Ltd. lost $2.33 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Galmed Pharmaceuticals Ltd. make?
Galmed Pharmaceuticals Ltd. generated revenue of $0.00 over the trailing twelve months.
What is the 52-week range for GLMD?
GLMD has traded between $0.41 and $1.26 over the past 52 weeks, and the last price is 61.0% below that high.
Is Galmed Pharmaceuticals Ltd. profitable?
Yes. Galmed Pharmaceuticals Ltd. keeps 0.00% of revenue as net income over the trailing twelve months.
What is the analyst price target for GLMD?
Wall Street analysts rate GLMD Buy.
What sector is Galmed Pharmaceuticals Ltd. in?
Galmed Pharmaceuticals Ltd. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in IL .
Who is the CEO of Galmed Pharmaceuticals Ltd.?
Allen Baharaff is the chief executive of Galmed Pharmaceuticals Ltd., which employs 3 people.
Where can I track GLMD in real time?
QFI Terminal shows GLMD with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See GLMD live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open GLMD in Terminal See plans